Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

DIGITAL DROPLET PCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT-FREE REMISSION OUTCOME.

Colafigli G, Scalzulli E, Porrazzo M, Diverio D, Loglisci MG, Latagliata R, Guarini A, Foà R, Breccia M.

Hematol Oncol. 2019 Jul 19. doi: 10.1002/hon.2650. [Epub ahead of print] No abstract available.

PMID:
31321792
2.

Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia.

Santopietro M, Miano M, Palumbo G, Zhang K, Cardarelli L, Chiaretti S, Peragine N, Nanni M, Diverio D, Mancini F, Testi AM, Moleti ML, Foà R, Giona F.

Acta Haematol. 2019 May 21:1-2. doi: 10.1159/000497137. [Epub ahead of print] No abstract available.

PMID:
31112981
3.

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.

Molica M, Colafigli G, Scalzulli E, Alunni Fegatelli D, Chiatamone Ranieri S, Rizzo L, Diverio D, Efficace F, Latagliata R, Foà R, Breccia M.

Ann Hematol. 2019 Aug;98(8):1891-1904. doi: 10.1007/s00277-019-03706-x. Epub 2019 May 11.

PMID:
31079264
4.

Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.

Strocchio L, Gurnari C, Santoro N, Putti MC, Micalizzi C, Zecca M, Cuccurullo R, Girardi K, Diverio D, Testi AM, Lo-Coco F, Locatelli F.

Br J Haematol. 2019 Apr;185(2):360-363. doi: 10.1111/bjh.15507. Epub 2018 Jul 20. No abstract available.

PMID:
30028005
5.

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.

Cicconi L, Breccia M, Franceschini L, Latagliata R, Molica M, Divona M, Diverio D, Rizzo M, Ottone T, Iaccarino L, Alfonso V, Foa R, Voso MT, Lo-Coco F.

Ann Hematol. 2018 Oct;97(10):1797-1802. doi: 10.1007/s00277-018-3400-z. Epub 2018 Jun 27.

PMID:
29951912
6.

Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?

Latagliata R, Breccia M, Carmosino I, Cesini L, De Benedittis D, Mohamed S, Vozella F, Molica M, Campanelli M, De Luca ML, Colafigli G, Quattrocchi L, Loglisci MG, Massaro F, Canichella M, Diverio D, Mancini M, Alimena G, Foà R.

Eur J Haematol. 2018 Jun 13. doi: 10.1111/ejh.13110. [Epub ahead of print]

PMID:
29896890
7.

Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.

Testi AM, Pession A, Diverio D, Grimwade D, Gibson B, de Azevedo AC, Moran L, Leverger G, Elitzur S, Hasle H, van der Werff ten Bosch J, Smith O, De Rosa M, Piciocchi A, Lo Coco F, Foà R, Locatelli F, Kaspers GJL.

Blood. 2018 Jul 26;132(4):405-412. doi: 10.1182/blood-2018-03-836528. Epub 2018 May 22.

PMID:
29789356
8.

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib.

Breccia M, Molica M, Colafigli G, Massaro F, Quattrocchi L, Latagliata R, Mancini M, Diverio D, Guarini A, Alimena G, Foà R.

Oncotarget. 2017 Dec 26;9(7):7534-7540. doi: 10.18632/oncotarget.23691. eCollection 2018 Jan 26.

9.

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.

Breccia M, Colafigli G, Molica M, Scalzulli E, Diverio D, Latagliata R, Guarini A, Foà R.

Am J Hematol. 2017 Dec;92(12):E668-E670. doi: 10.1002/ajh.24916. Epub 2017 Oct 19. No abstract available.

10.

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.

Molica M, Canichella M, Colafigli G, Latagliata R, Diverio D, Alimena G, Foà R, Breccia M.

Br J Haematol. 2018 Aug;182(3):427-429. doi: 10.1111/bjh.14783. Epub 2017 Jul 5. No abstract available.

PMID:
28677850
11.

Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.

Molica M, Breccia M, Colafigli G, Massaro F, Quattrocchi L, Mancini M, Diverio D, Latagliata R, Foà R.

Br J Haematol. 2018 Apr;181(2):275-278. doi: 10.1111/bjh.14560. Epub 2017 Feb 17. No abstract available.

PMID:
28211562
12.

Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib.

Giona F, Saglio G, Santopietro M, Menna G, Putti MC, Micalizzi C, Iaria G, Santoro N, Ladogana S, Mura R, Burnelli R, Consarino C, Cosmi C, Moleti ML, Leszl A, Tucci F, Nanni M, Diverio D, Biondi A, Locatelli F, Foà R.

Br J Haematol. 2018 Mar;180(6):895-898. doi: 10.1111/bjh.14458. Epub 2016 Dec 16. No abstract available.

13.

Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol.

Testi AM, Moleti ML, Canichella M, Mohamed S, Diverio D, de Propris MS, Locatelli F, Lo Coco F, Foà R.

Leuk Lymphoma. 2017 Apr;58(4):999-1001. doi: 10.1080/10428194.2016.1222377. Epub 2016 Sep 23. No abstract available.

PMID:
27658340
14.

Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia.

Chisini M, Stefanizzi C, Ceglie T, Raponi S, Vozella F, Colafigli G, Salaroli A, D'Angiò M, Mancini M, Diverio D, Breccia M, Mancini F, Minotti C, Trisolini S, Capria S, Testi AM, Guarini A, Latagliata R, De Propris MS, Foà R.

Hematol Oncol. 2017 Dec;35(4):804-809. doi: 10.1002/hon.2331. Epub 2016 Jul 12.

PMID:
27400753
15.

Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience.

Giona F, Moleti ML, De Benedittis D, Santopietro M, Nanni M, Testi AM, Orlando S, Iori AP, Piciocchi A, Gottardi E, Barberi W, Diverio D, Saglio G, Foà R.

Br J Haematol. 2016 Jun;173(5):749-53. doi: 10.1111/bjh.13991. Epub 2016 Feb 23.

PMID:
26913809
16.

Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.

Latagliata R, Carmosino I, Vozella F, Volpicelli P, De Angelis F, Loglisci MG, Salaroli A, De Luca ML, Montagna C, Serrao A, Molica M, Diverio D, Nanni M, Mancini M, Breccia M, Alimena G.

Hematol Oncol. 2017 Jun;35(2):232-236. doi: 10.1002/hon.2274. Epub 2015 Dec 9.

PMID:
26648184
17.

Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib.

Breccia M, Colafigli G, Molica M, De Angelis F, Quattrocchi L, Latagliata R, Mancini M, Diverio D, Alimena G.

Br J Haematol. 2016 Jun;173(6):945-6. doi: 10.1111/bjh.13649. Epub 2015 Aug 25. No abstract available.

PMID:
26304741
18.

Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy.

Breccia M, Stefania de Propris M, Molica M, Colafigli G, Minotti C, Diverio D, Latagliata R, Guarini A, Lo-Coco F, Foà R.

Am J Hematol. 2015 Sep;90(9):E181-2. doi: 10.1002/ajh.24033. Epub 2015 Jul 14. No abstract available.

19.

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response.

Latagliata R, Romano A, Mancini M, Breccia M, Carmosino I, Vozella F, Montagna C, Volpicelli P, De Angelis F, Petrucci L, Serrao A, Molica M, Salaroli A, Diverio D, Alimena G.

Leuk Lymphoma. 2016;57(1):99-102. doi: 10.3109/10428194.2015.1043548. Epub 2015 Oct 5.

PMID:
25997497
20.

Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.

Giona F, Putti MC, Micalizzi C, Menna G, Moleti ML, Santoro N, Iaria G, Ladogana S, Burnelli R, Consarino C, Varotto S, Tucci F, Messina C, Nanni M, Diverio D, Biondi A, Pession A, Locatelli F, Piciocchi A, Gottardi E, Saglio G, Foà R.

Br J Haematol. 2015 Aug;170(3):398-407. doi: 10.1111/bjh.13453. Epub 2015 Apr 20.

PMID:
25891192
21.

Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.

Breccia M, Latagliata R, Molica M, Colafigli G, Mancini M, Diverio D, Tafuri A, Alimena G.

Am J Hematol. 2015 May;90(5):E95-6. doi: 10.1002/ajh.23972. Epub 2015 Mar 30. No abstract available.

22.

Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline.

Molica M, Zacheo I, Diverio D, Alimena G, Breccia M.

Br J Haematol. 2015 Apr;169(1):148-50. doi: 10.1111/bjh.13184. Epub 2014 Oct 9. No abstract available.

PMID:
25296902
23.

Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia.

Giona F, Saglio G, Moleti ML, Piciocchi A, Rea M, Nanni M, Marzella D, Testi AM, Mariani S, Laurino M, Diverio D, Gottardi E, Foà R.

Br J Haematol. 2015 Jan;168(2):305-8. doi: 10.1111/bjh.13103. Epub 2014 Aug 27. No abstract available.

PMID:
25160793
24.

Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells.

Breccia M, De Propris MS, Stefanizzi C, Raponi S, Molica M, Colafigli G, Minotti C, Latagliata R, Diverio D, Guarini A, Foà R.

Ann Hematol. 2014 Nov;93(11):1819-23. doi: 10.1007/s00277-014-2130-0. Epub 2014 Jun 10.

PMID:
24912771
25.

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence.

Giona F, Teofili L, Capodimonti S, Laurino M, Martini M, Marzella D, Palumbo G, Diverio D, Foà R, Larocca LM.

Blood. 2014 Jun 5;123(23):3677-9. doi: 10.1182/blood-2014-04-572040. No abstract available.

26.

FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis.

Breccia M, Loglisci G, Loglisci MG, Ricci R, Diverio D, Latagliata R, Foà R, Lo-Coco F.

Haematologica. 2013 Dec;98(12):e161-3. doi: 10.3324/haematol.2013.095380. No abstract available.

27.

Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib.

Breccia M, Loglisci G, Salaroli A, Serrao A, Mancini M, Diverio D, Latagliata R, Alimena G.

Cancer Lett. 2013 Jun 1;333(1):32-5. doi: 10.1016/j.canlet.2012.12.018. Epub 2013 Jan 3.

PMID:
23291359
28.

Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia.

Latagliata R, Isidori A, Breccia M, Carmosino I, Vozella F, Volpicelli P, Finsinger P, Barulli S, Loglisci G, Santopietro M, Federico V, Diverio D, Nanni M, Mancini M, Visani G, Alimena G.

Acta Haematol. 2013;129(2):126-34. doi: 10.1159/000343384. Epub 2012 Nov 28.

29.

Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients.

Capria S, Trisolini SM, Minotti C, Stefanizzi C, Cardarelli L, Cartoni C, Diverio D, De Propris MS, Mancini M, Micozzi A, Foà R, Meloni G.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012072. doi: 10.4084/MJHID.2012.072. Epub 2012 Nov 6.

30.

High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation.

De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B, Foà R, Guarini A.

Haematologica. 2011 Oct;96(10):1548-51. doi: 10.3324/haematol.2011.043786. Epub 2011 Jul 26.

31.

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.

Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups.

Blood. 2011 May 5;117(18):4716-25. doi: 10.1182/blood-2010-08-302950. Epub 2011 Mar 8.

32.

Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.

Breccia M, Santopietro M, Cannella L, Federico V, Loglisci G, Serrao A, Petrucci L, Salaroli A, Nanni M, De Propris MS, Diverio D, Alimena G.

Leuk Res. 2011 Jun;35(6):e91-2. doi: 10.1016/j.leukres.2011.01.026. Epub 2011 Feb 11. No abstract available.

PMID:
21316103
33.

Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention.

Breccia M, Orlandi SM, Latagliata R, Grammatico S, Diverio D, Mancini M, Loglisci G, Salaroli A, Federico V, Santopietro M, Alimena G.

Br J Haematol. 2011 Jan;152(1):119-21. doi: 10.1111/j.1365-2141.2010.08380.x. Epub 2010 Oct 11. No abstract available.

PMID:
21029071
34.

A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia.

Gianfelici V, Diverio D, Breccia M, Buffolino S, Derme V, Di Lascio A, Marinelli M, Santangelo S, Meloni G, Foà R.

Ann Hematol. 2011 Jul;90(7):845-6. doi: 10.1007/s00277-010-1092-0. Epub 2010 Oct 6. No abstract available.

PMID:
20924583
35.

"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia.

Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R, Diverio D, Frustaci A, Loglisci G, Mancini M, Santopietro M, Stefanizzi C, Volpicelli P, Vozella F, Alimena G.

Leuk Res. 2010 Nov;34(11):1472-5. doi: 10.1016/j.leukres.2010.07.001. Epub 2010 Aug 13.

PMID:
20708799
36.

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.

Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group.

Blood. 2010 Oct 28;116(17):3171-9. doi: 10.1182/blood-2010-03-276196. Epub 2010 Jul 19.

37.

A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes.

Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, Testa U, Pelosi E, Piaggio G, Sacchi A, Lavorgna S, Lo-Coco F, Blandino G, Levrero M, Rizzo MG.

Oncogene. 2009 Nov 12;28(45):4034-40. doi: 10.1038/onc.2009.255. Epub 2009 Sep 14.

PMID:
19749800
38.

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.

Breccia M, Cannella L, Stefanizzi C, Latagliata R, Nanni M, Diverio D, Santopietro M, Federico V, Alimena G.

Hematol Oncol. 2010 Jun;28(2):89-92. doi: 10.1002/hon.920.

PMID:
19728398
39.

An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia.

Raponi S, De Propris MS, Wai H, Intoppa S, Elia L, Diverio D, Vitale A, Foà R, Guarini A.

Haematologica. 2009 Dec;94(12):1767-70. doi: 10.3324/haematol.2009.010900. Epub 2009 Jul 16.

40.

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, Diverio D, Jones K, Aslett H, Batson E, Rennie K, Angell R, Clark RE, Solomon E, Lo-Coco F, Wheatley K, Burnett AK.

J Clin Oncol. 2009 Aug 1;27(22):3650-8. doi: 10.1200/JCO.2008.20.1533. Epub 2009 Jun 8.

PMID:
19506161
41.

PLZF-mediated control on c-kit expression in CD34(+) cells and early erythropoiesis.

Spinello I, Quaranta MT, Pasquini L, Pelosi E, Petrucci E, Pagliuca A, Castelli G, Mariani G, Diverio D, Foà R, Testa U, Labbaye C.

Oncogene. 2009 Jun 11;28(23):2276-88. doi: 10.1038/onc.2009.87. Epub 2009 May 4.

PMID:
19421145
42.

Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations.

Alimena G, Breccia M, Latagliata R, Grammatico S, Matturro A, Capria S, De Propris MS, Diverio D, Meloni G.

Leuk Res. 2009 Aug;33(8):e134-6. doi: 10.1016/j.leukres.2009.02.018. Epub 2009 Mar 14. No abstract available.

PMID:
19286256
43.

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.

Breccia M, Frustaci AM, Cannella L, Stefanizzi C, Latagliata R, Cartoni C, Diverio D, Guarini A, Nanni M, Rago A, Cimino G, Alimena G.

Hematol Oncol. 2009 Sep;27(3):148-53. doi: 10.1002/hon.889.

PMID:
19274612
44.

Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation.

Saulle E, Riccioni R, Coppola S, Parolini I, Diverio D, Riti V, Mariani G, Laufer S, Sargiacomo M, Testa U.

Br J Haematol. 2009 May;145(3):399-411. doi: 10.1111/j.1365-2141.2009.07627.x. Epub 2009 Feb 24.

PMID:
19245429
45.

Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.

Breccia M, Cannella L, Stefanizzi C, Santopietro M, De Cuia R, Diverio D, Alimena G.

Leuk Res. 2009 May;33(5):645-8. doi: 10.1016/j.leukres.2008.10.024. Epub 2008 Dec 4.

PMID:
19062090
46.

Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.

Riccioni R, Diverio D, Riti V, Buffolino S, Mariani G, Boe A, Cedrone M, Ottone T, Foà R, Testa U.

Br J Haematol. 2009 Feb;144(3):376-87. doi: 10.1111/j.1365-2141.2008.07491.x. Epub 2008 Nov 13.

PMID:
19036083
47.

Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin.

Breccia M, Latagliata R, Carmosino I, Cannella L, Diverio D, Guarini A, De Propris MS, Petti MC, Avvisati G, Cimino G, Mandelli F, Lo-Coco F.

Haematologica. 2008 Dec;93(12):1918-20. doi: 10.3324/haematol.13510. Epub 2008 Oct 22. No abstract available.

48.

An acute promyelocytic leukaemia patient with a new atypical promyelocytic leukemia breakpoint.

Cenfra N, De Cave F, Minotti C, Ghia E, Rago A, Codacci Pisanelli G, Diverio D, Cimino G.

Br J Haematol. 2008 Sep;142(5):854-6. doi: 10.1111/j.1365-2141.2008.07253.x. No abstract available.

PMID:
18573113
49.

Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.

Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M, Testoni N, Bardi A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M, Amadori S, Mandelli F, Pelicci PG, Mecucci C, Falini B, Saglio G; Acute Leukemia Working Party of the GIMEMA group.

Haematologica. 2008 Jul;93(7):1017-24. doi: 10.3324/haematol.12004. Epub 2008 May 27.

50.

Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients.

Breccia M, Latagliata R, Carmosino I, Guarini A, Diverio D, De Cuia R, Cimino G, Alimena G.

Leuk Lymphoma. 2008 May;49(5):994-7. doi: 10.1080/10428190801947567. No abstract available.

PMID:
18464120

Supplemental Content

Loading ...
Support Center